scholarly journals The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Yi-Kun Kang ◽  
Xue Wang ◽  
Nan-Lin Hu ◽  
Jian Yue ◽  
Yi-Ran Si ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Early Breast Cancer ◽  
Ovarian Function ◽  
Young Patients ◽  
Lipid Profiles ◽  
Breast Cancer Patients ◽  
Premenopausal Breast Cancer ◽  
Ovarian Function Suppression ◽  
Younger Age

This study aimed to evaluate and compare the effects of various endocrine therapies on lipid profiles in young patients with breast cancer. A retrospective, single-center study was performed to investigate the effects of tamoxifen (TAM), tamoxifen plus ovarian function suppression (TAM+OFS), and aromatase inhibitors plus ovarian function suppression (AI+OFS) on lipid profiles during the 60 months of endocrine therapy in hormone receptor-positive patients aged <40 with early breast cancer. The primary endpoint was the cumulative incidence of lipid events, and the secondary endpoints were the changes in lipid profiles. A total of 230 young patients were included with the mean age of 35.7 years old. The patients in TAM group had significantly lower incidence of 5-year lipid events than those in TAM+OFS group (7.4% versus 21.3%; P=0.016) and AI+OFS group (7.4% versus 21.6%; P=0.009). The incidence of fatty liver was significantly higher in TAM+OFS group than TAM group (52.5%versus 30.9%; P=0.043). Lipid events were associated with younger age (odds ratio (OR)=0.865, 95% confidence interval (CI): 0.780-0960; P=0.006), higher baseline LDL-C (OR=14.959, 95% CI: 4.379-51.105; P<0.001), and use of OFS (OR=3.557, 95% CI: 1.151-10.989; P=0.027). Therefore, application of OFS, with younger age and higher baseline LDL-C, may increase the incidence of lipid events in premenopausal breast cancer. More care should be taken for lipid profiles during the endocrine therapy for young breast cancer patients.

scholarly journals Distribution of dyslipidemia in Chinese early breast cancer patients at diagnosis and comparison of dyslipidemia incidence following different endocrine therapies: a population-based cohort study

2021 ◽  
Author(s):  
Junren Wang ◽  
Jin Yin ◽  
Jiajun Qiu ◽  
Jingwen Jiang ◽  
Yao Hu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Ovarian Function ◽  
Cox Regression ◽  
Absolute Risk ◽  
Concomitant Disease ◽  
Breast Cancer Patients ◽  
Ovarian Function Suppression ◽  
Abnormal Rate ◽  
Premenopausal Patients

Abstract Background Dyslipidemia increases the risk of cardiovascular disease death in breast cancer (BC). Based on the large West China Hospital (WCH) BC cohort, we aimed to clarify dyslipidemia prevalence at diagnosis and compare the risk of dyslipidemia induced by different endocrine and menopause status. Methods 5917 EBC female patients recorded in WCH BC cohort, diagnosed between 2008.10 and 2017.04, were included for baseline analysis. 1883 patients receiving endocrine therapy (selective estrogen receptor modulator (SERM) or aromatase inhibitor (AI), with or without ovarian function suppression) with initial normal blood lipids were included for comparison study. Dyslipidemia was defined as abnormality of cholesterol/LDL/ HDL/triglyceride. Risk accumulation function was used to calculate the incidence of dyslipidemia to assess absolute risk, and the multivariate COX regression model was used to calculate the relative risk of dyslipidemia between groups. Results 16.5% of EBC patients had dyslipidemia at diagnosis. Among EBC patients receiving endocrine therapy, the accumulated incidence of dyslipidemia within 5 years in menopausal patients was higher than that in premenopausal patients (Adjusted HR [95%CI], 1.29 [1.04–1.59], 42.6 % vs 32.6%, P = 0.0186). In premenopausal patients, the risk of abnormal TC in OFS + AI group was significantly higher than SERM group (adjusted HR, 3.50 [ 1.74–7.02], P < 0.001, 5-year abnormal rate 22.0% vs 3.5%), and that of abnormal LDL-C was also increased(adjusted HR, 6.71 [ 3.16–14.26], P < 0.001, 5-year abnormal rate 12.2% vs 1.4%). In menopausal patients, the risk of abnormal TC or LDL-C showed the similar trend in AI group compared to SERM group. Conclusions Dyslipidemia is common concomitant disease in Chinese BC patients and needs to be closely monitored. Irrespective of menopause, AIs treatment causes higher risk of TC/LDL-C dyslipidemia than SERM.

Sign in / Sign up

Export Citation Format

Share Document